Real-world clinical outcomes of meropenem/vaborbactam for treatment of carbapenem-resistant Enterobacterales infections
ABSTRACT: Objectives: Real-world data regarding the effectiveness of meropenem/vaborbactam (MVB) in the treatment of carbapenem-resistant Enterobacterales (CRE) infections remain limited. In this retrospective case series, we describe the outcomes of patients who received MVB for serious CRE infect...
Guardado en:
Autores principales: | Helen L. Zhang, Leigh Cressman, Ebbing Lautenbach |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/94ac77b172b04ac2b1060dd9d664631d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
In Vitro Activity Comparison of Ceftazidime–Avibactam and Aztreonam–Avibactam Against Bloodstream Infections With Carbapenem-Resistant Organisms in China
por: Wei Yu, et al.
Publicado: (2021) -
The world-wide spread of carbapenem-resistant Enterobacterales
por: Arjana TAMBIC ANDRASEVIC, et al.
Publicado: (2021) -
The world-wide spread of carbapenem-resistant Enterobacterales
por: Arjana TAMBIC ANDRASEVIC, et al.
Publicado: (2021) -
Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections
por: Helio S. Sader, et al.
Publicado: (2021) -
Intestinal Dysbiosis in Carriers of Carbapenem-Resistant <italic toggle="yes">Enterobacteriaceae</italic>
por: Hila Korach-Rechtman, et al.
Publicado: (2020)